- Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples.
- Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%.
- Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells.
VolitionRx (VNRX) shares ripped more than 34% in Wednesday’s pre-market trade before paring gains to hover 16% higher in the opening trade after the company announced proof-of-concept data from a blinded validation cohort for the detection of cancer.
The company said that it has developed a new liquid biopsy method, and during a blind validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.
Retail sentiment on Stocktwits around Volition trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.
Detection Rates Across Cancer Stages
Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples. Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%.
"We are now releasing the data from a blinded validation cohort of 81 subjects and are extremely encouraged by the results, particularly in early-stage cancer detection,” said Volition’s Chief Scientific Officer, Jake Micallef.
The company’s Chief Commercial Officer, Gael Forterre, said that this technology represents a Total Addressable Market of nearly $23 billion for human Multi-Cancer Early Detection (MCED) tests, and $13 billion for Minimal Residual Disease (MRD) tests on an annualized basis.
“We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible,” Forterre added.
What Is Capture-Seq?
Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells. This makes it hard to detect the disease.
The company says its method solves this problem, producing more than 99% pure cancer-derived plasma DNA sequence sets for liquid biopsy. This filters out the noise and improves detection accuracy.
VNRX stock is down 23% year-to-date and 63% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 15% over the past 12 months.
Also See: AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
For updates and corrections, email newsroom[at]stocktwits[dot]com.